激素联合个性化药物治疗非动脉炎性前部缺血性视神经病变的疗效

 目的 探讨激素联合个性化药物治疗非动脉炎性前部缺血性视神经病变(non-arteritic anterior ischemic optic neuropathy, NAION)的效果。方法 选取NAION患者56例(61眼),根据其病因、发病时间、眼部检查、视野检查及眼底荧光血管造影(FFA)结果,制定激素联合个性化药物治疗方案,观察治疗前后视力、视野、眼底改善情况,判断综合疗效。结果 治疗后56例(61眼)视力均明显改善;治疗前56例(61眼)视野均出现特征性改变,治疗后视野缺损范围较治疗前缩小30°以上者48眼,显效率78.7%;治疗前FFA检查56例(61眼)荧光造影特征性改变, 治疗后54眼荧光造影改善,显效率88.5%。结论 激素联合个性化药物治疗,对NAION病预后有明显改善作用。

Therapeutic effect of hormone combined with individualized drug therapy against non-arteritic anterior ischemic optic neuropathy

Objective To study the therapeutic effect of hormone combined with an individualized drug therapy against non-arteritic anterior ischemic optic neuropathy (NAION). Methods A total of 56 cases(61 eyes) diagnosed with NAION between January 2012 and December 2015 were selected. According to etiology,oneset time of disease and results of ocular examination,visual field examination and fundus fluorescence angiography(FFA), treatment regimens were chosen that involved hormone combined with individualized medication. Improvements of visual acuity、visual fields and FFA after treatment were observed. The overall curative effect was evaluated. Results Vision was improved in each of the 56 cases (61 eyes)after treatment.Before treatment, characteristic changes of the visual field were detected in all the 61 eyes. After treatment, the range of the visual field defect was reduced by at least 30° in 48 eyes, and the effective rate was 78.7%. FFA confirmed 56 cases of characteristic changes in fluorescein angiography before treatment. After treatment, the fluorescein angiography was significantly improved in 54 eyes, and the effective rate was 88.5%. Conclusions The treatment of NAION with hormone combined with individualized medication can considerably improve the prognosis of patients.